Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

COVID-19 testing

- PMLiVE

AstraZeneca to supply US government with 500,000 additional doses of its COVID-19 antibody

AZD7442 is a long-acting antibody combination that could help to prevent and treat COVID-19

- PMLiVE

WHO backs emergency use of J&J’s one-dose COVID-19 vaccine

Vaccine is already approved for emergency use by the European Commission and the FDA

- PMLiVE

Safety review shows ‘no evidence’ that AZ’s vaccine causes increased risk of blood clots

AZ's vaccine continues to be backed by the EMA and the EMA’s Pharmacovigilance Risk Assessment Committee

- PMLiVE

Novavax COVID-19 vaccine found to be 86% effective against UK variant

Phase 2b trial also finds vaccine efficacy of 55.4% against South Africa variant

- PMLiVE

J&J’s one-dose COVID-19 vaccine granted EU authorisation

Company aiming to begin vaccine delivery to EU in the second half of April

- PMLiVE

EMA says there is ‘no indication’ AZ/Oxford’s COVID-19 vaccine causes blood clots

Agency’s safety committee added vaccine’s benefits continue to outweigh risks

- PMLiVE

Moderna launches COVID-19 vaccine booster study to address new variants

First participants receive company’s modified vaccine candidates

- PMLiVE

GSK, Vir seek EUA after scoring positive results for COVID-19 antibody VIR-7831

VIR-7831 reduced the risk of hospitalisation/death by 85% in high-risk COVID-19 patients

- PMLiVE

EMA starts rolling review of Lilly’s COVID-19 antibodies

CHMP will review the combination of bamlanivimab and etesemivab as well as bamlanivimab monotherapy

- PMLiVE

Stakeholder meeting kick-starts dialogue on COVID-19 vaccine supply chain issues

Meeting discussed potential solutions to COVID-19 vaccine manufacturing bottlenecks

- PMLiVE

Pfizer/BioNTech could supply three billion doses of COVID-19 vaccine in 2022

J&J reportedly facing vaccine supply issues in the EU

- PMLiVE

Pfizer/BioNTech’s COVID-19 vaccine neutralises Brazil variant, suggests study

Neutralisation of variant 'roughly equivalent' to original SARS-CoV-2 strain

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links